Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.41 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25524054 | 0.77 | CYP11B2 (0.62) | PIM1PIM2PIM3CYP11B2CYP11B1 | |
| SCHEMBL21044144 | 0.75 | CYP11B2 (0.50) | PIM1CYP11B2CYP11B1CTPS1 | |
| SCHEMBL32663050 | 0.75 | CYP11B2 (0.50) | PIM1CYP11B2CYP11B1CTPS1 | |
| SCHEMBL21392091 | 0.74 | MTOR (0.41) | PIM1PIM2PIM3MAPK1CTPS1 | |
| SCHEMBL22869121 | 0.73 | CYP11B2 (0.45) | PIM1PIM3CYP11B2CYP11B1 | |
| SCHEMBL22869136 | 0.73 | CYP11B2 (0.72) | CYP11B2CYP11B1 | |
| SCHEMBL21373703 | 0.73 | CYP11B2 (0.67) | PIM1PIM2PIM3CYP11B2CYP11B1 | |
| SCHEMBL9904760 | 0.71 | FYN (0.58) | PIM1PIM2PIM3CYP11B2CYP11B1 | |
| SCHEMBL21373760 | 0.70 | CYP11B2 (0.49) | PIM1PIM2PIM3CYP11B2CYP11B1 | |
| SCHEMBL21044419 | 0.70 | PIM2 (0.51) | PIM1PIM2PIM3CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768674-B1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2024-01-03 | — | — | EP | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | PIM1 1525/4885PIM2 2031/4885PIM3 2231/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | PIM1 1525/4885PIM2 2031/4885PIM3 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.